Clinical trial
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement…
NCT00430625 · Shire, Industry · Completed
Key facts
| NCT number | NCT00430625 |
|---|---|
| Title | A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease |
| Official title | A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gaucher Disease, Type 1 |
| Intervention type | Biological |
| Interventions | VPRIV ® |
| Enrollment | 25 |
| Start date | Feb 15, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Feb 2, 2007 |
| Last update posted | Jun 29, 2021 |
| Countries | Argentina, Israel, Paraguay, Russia, Tunisia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: